Scarica l'app Stockscreener
31.53
3.43%
-1.12
Dopo l'orario di chiusura:
31.53
Precedente Chiudi:
$32.65
Aprire:
$30.44
Volume 24 ore:
609.17K
Relative Volume:
1.32
Capitalizzazione di mercato:
$658.33M
Reddito:
$1.77M
Utile/perdita netta:
$-123.74M
Rapporto P/E:
-3.4384
EPS:
-9.17
Flusso di cassa netto:
$-95.21M
1 W Prestazione:
-16.74%
1M Prestazione:
-18.10%
6M Prestazione:
-49.54%
1 anno Prestazione:
-37.27%
Intervallo 1D:
$30.00
$34.05
Intervallo di 1 settimana:
$30.00
$37.91
Portata 52W:
$30.00
$91.83
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Nome
Praxis Precision Medicines Inc
Settore
Industria
Telefono
617-300-8460
Indirizzo
99 HIGH STREET, 30TH FLOOR, BOSTON
Confronta PRAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
31.53 | 658.33M | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-03 | Reiterato | H.C. Wainwright | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-08-05 | Iniziato | Oppenheimer | Outperform |
| 2024-06-24 | Iniziato | Needham | Buy |
| 2024-06-18 | Iniziato | Guggenheim | Buy |
| 2024-05-01 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-19 | Iniziato | Truist | Buy |
| 2022-06-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-26 | Iniziato | BofA Securities | Buy |
| 2021-04-26 | Iniziato | William Blair | Outperform |
| 2020-11-11 | Iniziato | Wedbush | Outperform |
| 2020-11-10 | Iniziato | Cowen | Outperform |
| 2020-11-10 | Iniziato | Evercore ISI | Outperform |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Corebridge Financial Inc. - Defense World
How to Take Advantage of moves in (PRAX) - news.stocktradersdaily.com
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Praxis Precision Medicines to Participate in Upcoming April Conferences - The Manila Times
CNS Drug Developer Praxis Sets Key Investor Presentations at Needham and Piper Conferences - Stock Titan
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Grants 8,763 Shares to New Employees in Compensation Package - Stock Titan
Teacher Retirement System of Texas Invests $305,000 in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate - Yahoo Finance
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by Swiss National Bank - Defense World
Praxis Precision Medicines to Present Late-Stage Data on CNS Disorders at AAN 2025 Annual Meeting - Nasdaq
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting - GlobeNewswire
Major Clinical Updates: Praxis Unveils Late-Stage Data for Epilepsy and Movement Disorders at AAN 2025 - Stock Titan
Charles Schwab Investment Management Inc. Acquires 5,840 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Bank of New York Mellon Corp - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by US Bancorp DE - Defense World
HC Wainwright Has Negative Estimate for PRAX Q1 Earnings - Defense World
Praxis Precision Medicines Updates on Programs and Finances - TipRanks
New York State Common Retirement Fund Boosts Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Rhumbline Advisers Cuts Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year Low Following Analyst Downgrade - Defense World
Praxis Adds Six New Hires With $33.55 Stock OptionsWhat's Behind This Talent Acquisition? - StockTitan
Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences - GlobeNewswire
Praxis Precision price target lowered to $85 from $150 at Needham - Yahoo Finance
CNS Therapy Developer PRAX Lines Up Five Major Investor ConferencesWhat's Their 2025 Strategy? - StockTitan
Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide (NASDAQ:PRAX) - Seeking Alpha
Praxis Precision Medicines (NASDAQ:PRAX) Given New $105.00 Price Target at HC Wainwright - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Cut to $85.00 by Analysts at Needham & Company LLC - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Given New $73.00 Price Target at Robert W. Baird - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Lowered to $85.00 at Truist Financial - Defense World
Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade) - Seeking Alpha
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate - Benzinga India
Praxis Precision (PRAX) Stock Price Target Cut By Half - AskTraders
Praxis Precision price target lowered to $85 from $175 at Truist - TipRanks
Praxis Precision Medicines Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Praxis Precision tanks on negative ulixacaltamide news - The Pharma Letter
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $65 From $111, Maintains Buy Rating - Marketscreener.com
Assessing Praxis Precision Medicine: Insights From 5 Financial Analysts - Benzinga
Praxis Precision Medicines: A Compelling Buy Amidst Promising Pipeline Developments - TipRanks
Praxis Presses Forward in Essential Tremor Despite Futility Finding From Trial Observers - MedCity News
Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down After Earnings Miss - Defense World
Praxis Precision Medicines (PRAX) Projected to Post Quarterly Earnings on Friday - MarketBeat
Praxis cites doubts over late-stage trial success: Wedbush downgrades (update) - MSN
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update - GlobeNewswire
Praxis to advance late-stage program for lead asset despite doubts over success - MSN
Praxis stock price target cut to $61 at TD Cowen By Investing.com - Investing.com Australia
Items Tagged with 'relutrigine' - BioWorld Online
Items Tagged with 'vormatrigine' - BioWorld Online
Praxis Aims To Complete ET Trial Despite Likely Primary Endpoint Miss - Citeline News & Insights
Praxis stock price target cut to $61 at TD Cowen - Investing.com India
Praxis Precision Medicines Inc Azioni (PRAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):